Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB […]
NB-UVB 311 nm
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Site-Specific Response
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best outcomes on face/neck, slower on acral sites. Typical schedule 2–3×/week for 24–48
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Safety (n≈150–200)
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo with best responses on face/neck; acral lesions remain hardest. Typical schedules: 2–3×/week, incremental
NB-UVB 311 nm vs PUVA in Vitiligo: Comparative Efficacy and Safety
Key Takeaways NB-UVB achieves comparable or superior facial repigmentation versus PUVA in multiple comparative studies, with fewer systemic adverse effects.
NB-UVB 311 nm for Vitiligo: Cohort Evidence, Protocols, Predictors, and Safety
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens
Vitiligo Research Map 1900–2025: Meta-Review, Timeline, and Methods
Key Takeaways Evidence for vitiligo has progressed from descriptive case series to randomized and phase-3 trials; the most mature clinical